Break-Even Holders Eyeing the $44 Milestone
The Injective (INJ) price dynamics reveal that 83% of active holders are at break-even, hinting they’re awaiting a price rebound. Concurrently, INJ’s active addresses have recently increased after a late March dip. Additionally, the EMA […]
